The Advanced Market Commitment for Pneumococcal Vaccines (AMC) has been enormously successful and has achieved its targets three years ahead of schedule. Its innovative approach has enabled 114 million children to be immunised across 57 countries and prevented 762,000 deaths from severe pneumonia. It is a tremendous example of the impact UK Aid has in delivering results.
The UK works closely with the Gavi Alliance and other AMC donors to ensure that our contribution to the AMC achieves the maximum impact and value for money. We have engaged in extensive discussions regarding the potential extension of Advanced Market Commitment pilot beyond the current end date of December 2020. However, given that the AMC has achieved all of its targets 3 years ahead of schedule, there is limited evidence an extension will deliver significant further benefits. The UK has pushed the AMC to develop and communicate a strategic use for any residual funds during the remaining life of the AMC and will continue to work with the Gavi Secretariat and donors to ensure the best use of these.